Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control

Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control

Alemtuzumab is a monoclonal antibody targeting CD52 on the surface of immune cells, approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). The purpose of this study was to analyze the repopulation of peripheral lymphocytes following alemtuzumab-induced lymphocyte depleti...

Full description

Bibliographic Details
Main Authors: Marina Rode von Essen, Helene Højsgaard Chow, Rikke Holm Hansen, Sophie Buhelt, Finn Sellebjerg
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Immunology
Subjects:
alemtuzumab therapy
multiple sclerosis
immune reconstitution
lymphocytes
disease activity
secondary autoimmunity
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249201/full

Similar Items

Similar Items